Oscar Health (OSCR) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| UBS | Maintained | Neutral | $36.00 from $26.00 | Oct 12, 2026 |
| Raymond James | Maintained | Outperform | $42.00 from $34.00 | Sep 18, 2026 |
| Baird | Maintained | Neutral | $33.00 from $27.00 | Sep 17, 2026 |
| Barclays | Maintained | Overweight | $49.00 from $39.00 | Sep 17, 2026 |
| Stephens & Co. | Maintained | Equal-Weight | $34.00 | Sep 17, 2026 |
| B of A Securities | Maintained | Underperform | $30.00 from $28.00 | Sep 17, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $27.00 from $20.00 | Aug 13, 2026 |
| Barclays | Maintained | Overweight | $39.00 from $35.00 | Aug 7, 2026 |
| UBS | Maintained | Neutral | $26.00 from $20.00 | Aug 7, 2026 |
| Barclays | Upgraded | Equal-Weight → Overweight | $35.00 from $30.00 | Jun 10, 2026 |
| Barclays | Maintained | Equal-Weight | $30.00 from $21.00 | May 26, 2026 |
| Baird | Maintained | Neutral | $19.00 from $15.00 | May 7, 2026 |
| Barclays | Maintained | Equal-Weight | $21.00 from $18.00 | May 7, 2026 |
| UBS | Maintained | Neutral | $20.00 from $15.00 | May 7, 2026 |
| Wolfe Research | Initiated Coverage | Peer Perform | — | May 6, 2026 |
| Jefferies | Upgraded | Underperform → Hold | $16.00 from $10.00 | Apr 20, 2026 |
| UBS | Upgraded | Sell → Neutral | $17.00 from $12.00 | Jan 9, 2026 |
| Barclays | Upgraded | Underweight → Equal-Weight | $18.00 from $13.00 | Jan 5, 2026 |
| Stephens & Co. | Initiated Coverage | Equal-Weight | $17.00 | Dec 11, 2025 |
| Piper Sandler | Upgraded | Neutral → Overweight | $25.00 from $13.00 | Nov 26, 2025 |
Frequently asked questions
What is the price target for OSCR stock?
The average 12-month analyst price target for Oscar Health (OSCR) is $35.86, with a high estimate of $49.00 and a low of $27.00, across 7 analysts.
Is OSCR a buy, sell, or hold?
Analysts covering Oscar Health currently average a Hold rating: 5 buy, 7 hold and 1 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for OSCR?
The average price target of $35.86 implies 5.30% upside from the last price of $34.05.
What is the latest analyst rating on OSCR?
On Oct 12, 2026, UBS maintained Oscar Health at Neutral with a price target of $36.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.